AbCellera Biologics Inc. announced that the United States Court of Appeals for the Federal Circuit has confirmed the validity of its U.S. Patent No. 10,087,408 related to microfluidic devices used for culturing and selectively recovering cells. The Federal Circuit upheld this decision by a Rule 36 Order, following a challenge by Bruker Cellular Analysis, Inc., which claimed the patent was invalid due to anticipation and obviousness over prior art. This patent is central to an ongoing multi-patent infringement litigation with Bruker. AbCellera expressed satisfaction with the ruling, emphasizing its commitment to defending its intellectual property.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.